Horm Metab Res 2008; 40(12): 907-910
DOI: 10.1055/s-0028-1087169
Humans, Clinical

© Georg Thieme Verlag KG Stuttgart · New York

The Fatty Acid Amide Hydrolase (FAAH) Pro129Thr Polymorphism is not Associated with Severe Obesity in Greek Subjects

D. Papazoglou 1 , I. Panagopoulos 2 , N. Papanas 1 , T. Gioka 3 , T. Papadopoulos 1 , P. Papathanasiou 1 , O. Kaitozis 1 , K. Papatheodorou 1 , E. Maltezos 1
  • 1Second Department of Internal Medicine, Medical School, Democritus University of Thrace, Alexandroupolis, Greece
  • 2Department of Clinical Genetics, Lund University Hospital, Lund, Sweden
  • 3Laboratory of Biochemistry, University Hospital of Alexandroupolis, Greece
Weitere Informationen

Publikationsverlauf

received 07.02.2008

accepted 10.06.2008

Publikationsdatum:
25. September 2008 (online)

Abstract

Fatty amid acid hydrolase (FAAH) has been implicated at both protein and gene level with obesity. An association between Pro129Thr variant of the FAAH gene and obesity has been described, but various studies have yielded conflicting results. Our aim was to determine whether this polymorphism is related to severe obesity and whether it confers a risk for variability of quantitative metabolic traits in a cohort of Greek obese subjects. Two groups of severely obese subjects (BMI > 40 kg/m2) were studied: a group of 158 metabolically healthy and a group of 145 obese subjects with metabolic syndrome, which were compared to a control group consisting of 121 lean individuals. We did not find any association between the Pro129Thr polymorphism with severe obesity in both subgroups of obese subjects, between these two subgroups (p= 0.11) or on basic anthropometric characteristics in the three groups. Statistically significant differences were found for glucose and HDL in metabolically healthy subjects and HDL in the control group. The borderline significant p-values were not significant after correction for multiple testing. We were unable to find robust evidence of an association of the Pro129Thr variant with severe obesity, and any related quantitative traits among the obese Greek subjects examined.

References

  • 1 Yanovski SZ, Yanovski JA. Obesity.  N Engl J Med. 2002;  346 591-602
  • 2 Schwarz PE, Reimann M, Li J, Bergmann A, Licinio J, Wong ML, Bornstein SR. The Metabolic syndrome – a global challenge for prevention.  Horm Metab Res. 2007;  39 777-780
  • 3 Barsh GS, Farooqi IS, O’Rahilly S. Genetics of body-weight regulation.  Nature. 2000;  404 644-651
  • 4 Jamshidi N, Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats.  Br J Pharmacol. 2001;  134 1151-1154
  • 5 Williams CM, Kirkham TC. Observational analysis of feeding induced by Delta9-THC and anandamide.  Physiol Behav. 2002;  76 241-250
  • 6 Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, Pagotto U. Endogenous cannabinoid system as a modulator of food intake.  Int J Obes Relat Metab Disord. 2003;  27 289-301
  • 7 Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endonnabinoid system in endocrine regulation and energy balance.  Endocr Rev. 2006;  27 73-100
  • 8 Kempf K, Hector J, Strate T, Schwarzloh B, Rose B, Herder C, Martin S, Algenstaedt P. Immune-mediated activation of the endocannabinoid system in visceral adipose tissue in obesity.  Horm Metab Res. 2007;  39 596-600
  • 9 Cravatt BF, Giang DK, Mayfield SM, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides.  Nature. 1996;  384 83-87
  • 10 Kurahashi Y, Ueda N, Suzuki H, Suzuki M, Yamamoto S. Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty-acid amide hydrolase.  Biochem Biophys Res Commun. 1997;  237 512-515
  • 11 Giang DK, Cravatt BF. Molecular characterization of human and mouse fatty acid amide hydrolases.  Proc Natl Acad Sci USA. 1997;  94 2238-2242
  • 12 Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use.  Proc Natl Acad Sci USA. 2002;  99 8394-8399
  • 13 Chiang KP, Gerber AL, Sipe JC, Cravatt BF. Reduced cellular expression and activity of the P129 T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use.  Hum Mol Genet. 2004;  13 2113-2119
  • 14 Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH).  Int J Obes. 2005;  29 755-759
  • 15 Jensen DP, Andreasen CH, Andersen MK, Hansen L, Eiberg H, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O. The functional Pro129Thr variant of the FAAH gene is not associated with various fat accumulation phenotypes in a population-based cohort of 5,801 whites.  J Mol Med. 2007;  85 445-449
  • 16 Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, Spertus JA, Costa F. American Heart Association. National Heart, Lung, and Blood Institute . Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive Summary.  Circulation. 2005;  112 e285-e290
  • 17 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.  Hypertension. 2003;  42 1206-1252
  • 18 Price RA, Lee JH. Risk ratios for obesity in families of obese African-American and Caucasian women.  Hum Hered. 2001;  15 135-140
  • 19 Drenick EJ, Bale GS, Seltzer F, Johnson DG. Excessive mortality and causes of death in morbidly obese men.  JAMA. 1980;  243 443-445
  • 20 Aberle J, Fedderwitz I, Klages N, George E, Beil FU. Genetic variation in two proteins of the endocannabinoid system and their influence on body mass index and metabolism under low fat diet.  Horm Metab Res. 2007;  39 395-397

Correspondence

D. Papazoglou

Patriarhou Grigoriou 97–99

68100 Alexandroupolis

Greece

Telefon: +30/255/107 47 25

Fax: +30/255/107 47 23

eMail: dpapazog@med.duth.gr